

# Obsessive-Compulsive Disorder Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/OCB8E3F39942EN.html>

Date: March 2022

Pages: 46

Price: US\$ 2,000.00 (Single User License)

ID: OCB8E3F39942EN

## Abstracts

Obsessive-Compulsive Disorder Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Obsessive-Compulsive Disorder - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Obsessive-Compulsive Disorder (Central Nervous System) pipeline landscape.

Obsessive-compulsive disorder (OCD) is characterized by unreasonable thoughts and fears (obsessions) that lead to do repetitive behaviors (compulsions). Symptoms include having repeated thoughts or images about many different things, such as fear of germs, dirt, or intruders, acts of violence, hurting loved ones, doing the same rituals over and over such as washing hands, locking, and unlocking doors, counting, keeping unneeded items, or repeating the same steps again and again. Risk factor includes family history. Treatment includes antidepressants and psychiatric medications.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Obsessive-Compulsive Disorder - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Obsessive-Compulsive Disorder (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of

action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Obsessive-Compulsive Disorder (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Obsessive-Compulsive Disorder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 1, 5 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Obsessive-Compulsive Disorder (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Obsessive-Compulsive Disorder (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Obsessive-Compulsive Disorder (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products

which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Obsessive-Compulsive Disorder (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Obsessive-Compulsive Disorder (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Obsessive-Compulsive Disorder (Central Nervous System)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Obsessive-Compulsive Disorder (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Obsessive-Compulsive Disorder (Central Nervous System) pipeline depth and focus of

Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

- Introduction
- Global Markets Direct Report Coverage
- Obsessive-Compulsive Disorder - Overview
- Obsessive-Compulsive Disorder - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Obsessive-Compulsive Disorder - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Obsessive-Compulsive Disorder - Companies Involved in Therapeutics Development
- Amorsa Therapeutics Inc
- Biogen Inc
- Biohaven Pharmaceutical Holding Company Ltd
- Cannabis Science Inc
- Evecxia Therapeutics Inc
- Octapharma AG
- Omeros Corp
- PharmaTher Holdings Ltd
- Phytecs
- Rugen Therapeutics R&D (Shanghai) Co Ltd
- Obsessive-Compulsive Disorder - Drug Profiles
- (betaine + ketamine) - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CBISOCD-001 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- EVX-101 - Drug Profile
- Product Description
- Mechanism Of Action

History of Events

immune globulin (human) - Drug Profile

Product Description

Mechanism Of Action

History of Events

OMS-527 - Drug Profile

Product Description

Mechanism Of Action

History of Events

PECS-101 - Drug Profile

Product Description

Mechanism Of Action

psilocybin - Drug Profile

Product Description

Mechanism Of Action

History of Events

rituximab - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Antagonize GRIN2B for Autism and Obsessive Compulsive Disorders - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Target NMDA Receptor for Obsessive Compulsive Disorder - Drug Profile

Product Description

Mechanism Of Action

troriluzole hydrochloride - Drug Profile

Product Description

Mechanism Of Action

History of Events

Obsessive-Compulsive Disorder - Dormant Projects

Obsessive-Compulsive Disorder - Discontinued Products

Obsessive-Compulsive Disorder - Product Development Milestones

Featured News & Press Releases

Aug 06, 2021: China NMPA approved the IND application for new glutamate modulator Troriluzole, signalling fresh hope for OCD patients

Jan 04, 2021: Biohaven begins pivotal Phase 3 trial of troriluzole in obsessive-compulsive disorder

Jun 24, 2020: Biohaven announces obsessive compulsive disorder (OCD) proof of concept phase 2/3 study results and program update

Sep 16, 2019: Omeros announces positive results from phase 1 study of its lead PDE7 inhibitor in development for addiction

Dec 21, 2017: Biohaven Enrolls First Patient In Pivotal Trial Of Trigriluzole In Patients With Obsessive-Compulsive Disorder

Oct 24, 2017: Biohaven Receives FDA May Proceed Letter for Phase 2/3 Clinical Trial of Trigriluzole in Patients with Obsessive-Compulsive Disorder

Jul 13, 2017: Biohaven Receives Notice Of Allowance From U.S. Patent And Trademark Office On Patent Application For Glutamate Modulating Prodrugs

Mar 19, 2013: Omeros Elucidates Mechanism Of PDE7 Inhibitors In Addiction

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Obsessive-Compulsive Disorder, 2022  
Number of Products under Development by Companies, 2022  
Number of Products under Development by Universities/Institutes, 2022  
Products under Development by Companies, 2022  
Products under Development by Universities/Institutes, 2022  
Number of Products by Stage and Target, 2022  
Number of Products by Stage and Mechanism of Action, 2022  
Number of Products by Stage and Route of Administration, 2022  
Number of Products by Stage and Molecule Type, 2022  
Obsessive-Compulsive Disorder - Pipeline by Amorsa Therapeutics Inc, 2022  
Obsessive-Compulsive Disorder - Pipeline by Biogen Inc, 2022  
Obsessive-Compulsive Disorder - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, 2022  
Obsessive-Compulsive Disorder - Pipeline by Cannabis Science Inc, 2022  
Obsessive-Compulsive Disorder - Pipeline by Evecxia Therapeutics Inc, 2022  
Obsessive-Compulsive Disorder - Pipeline by Octapharma AG, 2022  
Obsessive-Compulsive Disorder - Pipeline by Omeros Corp, 2022  
Obsessive-Compulsive Disorder - Pipeline by PharmaTher Holdings Ltd, 2022  
Obsessive-Compulsive Disorder - Pipeline by Phytects, 2022  
Obsessive-Compulsive Disorder - Pipeline by Rugen Therapeutics R&D (Shanghai) Co Ltd, 2022  
Obsessive-Compulsive Disorder - Dormant Projects, 2022  
Obsessive-Compulsive Disorder - Discontinued Products, 2022



## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Obsessive-Compulsive Disorder, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

## I would like to order

Product name: Obsessive-Compulsive Disorder Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/OCB8E3F39942EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/OCB8E3F39942EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

